Abstract
Background: Gaucher disease (GD) is due to deficiency of acid-β-glucosidase (ABG) and comprises a clinical spectrum with variable age of onset and severity. We evaluated a tandem mass spectrometry (MS/MS) method to measure ABG activity for high through-put screening. Methods: ABG activity was measured in 3.2mm punches from dry blood spots (DBS). Each punch was incubated for 21h with the substrate D-Glucosyl-β1-1β-N-dodecanoyl-D-erythro-sphingosine [C12-glucocerebroside (C36H69NO8)] and internal standard N-myristoyl-D-erythro-sphingosine [C14-ceramide (C32H63NO3)]. The product and internal standard were quantified using MS/MS. Results: ABG activities in anonymized newborn screening samples from NY State were (mean) 22.0 μmol/h/L ± (SD) 13.8 μmol/h/L (n=2088, median 19.9 μmol/h/L, 95%CI 22.59-21.41 μmol/h/L). The enzymatic activity in DBS from 10 treatment naïve adult Gaucher patients was less than 4.2 μmol/h/L. ABG activity was stable for 3. months at room temperature a 20% activity reduction was observed. Inter- and intra-run imprecisions were 8% and 13.7%, respectively. The limit of detection was 0.75 μmol/h/L and limit of quantification was 1.25 μmol/h/L. Conclusions: The measurement of ABG activities in DBS using MS/MS is suitable for high-throughput analysis of at-risk individuals and potentially for newborn screening for GD.
Original language | English (US) |
---|---|
Pages (from-to) | 343-346 |
Number of pages | 4 |
Journal | Clinica Chimica Acta |
Volume | 412 |
Issue number | 3-4 |
DOIs | |
State | Published - Jan 30 2011 |
Externally published | Yes |
Keywords
- Dry blood spot
- Enzyme
- Filter card
- Lysosomal
- Mass spectrometry
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical